IGC Pharma expands CALMA Phase 2 trial with Royal Jubilee Hospital

IGC Pharma (IGC) announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in Alzheimer’s dementia, to a new international site at Island Health’s Royal Jubilee Hospital in Victoria, British Columbia, Canada. This marks the CALMA trial’s continued growth across North America, aiming to increase access for patients and caregivers affected by Alzheimer’s disease and its neuropsychiatric symptoms. The addition of Royal Jubilee Hospital strengthens the trial’s clinical infrastructure and supports timely enrollment as the Company works toward trial completion. The CALMA Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of IGC-AD1 in managing agitation in patients with Alzheimer’s disease, a symptom that significantly impacts quality of life and care outcomes.